CORT News and Press, Corcept Therapeutics Incorporated From 03/06/23

2023-03-06 09:28:28 ET Corcept Therapeutics ( NASDAQ: CORT ), the maker of Cushing’s syndrome therapy Korlym added 10% pre-market Monday after the company announced a tender offer to buy back up to 7.5M shares of its common stock. The company said the share repu...

MENLO PARK, Calif., March 06, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (Nasdaq: CORT) (“ Corcept ”), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by...

Corcept Therapeutics Incorporated (CORT) Q4 2022 Earnings Conference Call February 28, 2023, 05:00 PM ET Company Participants Atabak Mokari - Chief Financial Officer Charlie Robb - Chief Business Officer Joseph Belanoff - Chief Executive Officer Bill Guyer - Chief ...

Corcept Therapeutics press release ( NASDAQ: CORT ): Q4 GAAP EPS of $0.15 misses by $0.08 . Revenue of $103M (+4.3% Y/Y) misses by $2.08M . 2023 revenue guidance of $430 – $450 million For further details see: Corcept Therapeutics GAAP EPS of $0.15 mis...

MENLO PARK, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the ho...

MENLO PARK, Calif., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report fourth quarter and full-year 2022 financial results and provide a corporate update on February 28, 2023. The company will also host a conference call that day at 5...

Summary Despite settling one of its disputes surrounding the Korlym label, investors were major sellers of Corcept equity in Q4 FY22. Question is, does the selloff represent a value proposition, and do current valuations make sense. On close inspection, we believe that paying 21x fo...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips If there’s a silver lining regarding the coronavirus pandemic, it’s that it demonstrated the importance of the top biotech stock picks for 2023. While medical innovations may seem frustratingly slow, the Covid-19 ...

Corcept Therapeutics ( NASDAQ: CORT ) announced an agreement with Hikma Pharmaceuticals ( OTCPK:HKMPF ) USA on Thursday to resolve the ongoing patent lawsuit related to Korlym®, an oral therapy indicated for patients with Cushing’s syndrome. The litigation was filed in...

MENLO PARK, Calif., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the ho...